SCHEMBL7623725

SCHEMBL7623725

CC(C)Cc1ccc(C(C)CNC(=N)C(C)c2ccc(CC(C)C)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR1 P25024 5/20 0.50
CXCR2 P25025 5/20 0.50
PTGS1 P23219 3/20 0.50
PTGS2 P35354 3/20 0.50
LMNA P02545 2/20 0.50
CYP2C9 P11712 2/20 0.50
AKR1C3 P42330 2/20 0.50
ALB P02768 1/20 0.50
ESR1 P03372 1/20 0.50
ALOX5 P09917 1/20 0.50
RARB P10826 1/20 0.50
ADRB3 P13945 1/20 0.50
NFKB1 P19838 1/20 0.50
HTR2A P28223 1/20 0.50
NR1I3 Q14994 1/20 0.50
SLC22A6 Q4U2R8 1/20 0.50
CXCL8 P10145 1/20 0.50
TSHR P16473 1/20 0.50
AKR1C2 P52895 1/20 0.50
BLM P54132 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2338545 0.80 CHRM1 (0.65) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL13433689 0.80 CXCR1 (0.56) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL2341090 0.80 CXCR1 (0.56) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL2338550 0.80 CHRM1 (0.65) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL2334888 0.80 CHRM1 (0.65) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL2336381 0.80 CXCR1 (0.56) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL13433700 0.79 PTGS1 (0.51) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL2341496 0.79 PTGS1 (0.51) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL2364054 0.79 CHRM1 (0.48) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL2341495 0.79 PTGS1 (0.51) CXCR1CXCR2PTGS1PTGS2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6444434-B1 COMPOUNDS INHIBITING THE ACTIVATION OF FX TO FXA BY TF/FVIIA. THE COMPOUNDS ARE ANTICOAGULANTS. THE INVENTION ALSO RELATES TO A METHOD OF IDENTIFYING A DRUG CANDIDATE. NOVO NORDISK A/S (DK) 2002-09-03 US disclosed
US-6238878-B1 DRUG SCREENING OF FACTOR VIII-TISSUE FACTOR INHIBITORS BY TESTING EFFECT ON FACTOR X ACTIVATION, FACTOR XA AMIDOLYTIC ASSAY, AND TISSUE FACTOR/FACTOR VIIA AMIDOLYTIC ASSAY; THEN SELECTING COMPOUND BASED ON RESULTS NOVO NORKISK AIS (DK) 2001-05-29 US disclosed